{"id":"ibalizumab-uiyk","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"},{"rate":"5-10%","effect":"Injection site reaction"}]},"_chembl":{"chemblId":"CHEMBL1743029","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the CD4 receptor, ibalizumab-uiyk blocks the interaction between HIV and the host cell, thereby inhibiting viral entry and replication. This mechanism of action is specific to CD4-expressing cells, such as T cells, and is thought to be responsible for the drug's antiviral effects.","oneSentence":"Ibalizumab-uiyk is a monoclonal antibody that binds to the CD4 receptor on T cells, preventing HIV entry and replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:59.359Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment-experienced HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT06071624","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML.","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2024-02-21","conditions":"Chronic Myelomonocytic Leukemia","enrollment":30},{"nctId":"NCT03829540","phase":"PHASE1","title":"CD4CAR for CD4+ Leukemia and Lymphoma","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2020-07-09","conditions":"T-cell Lymphoma, T-cell Leukemia","enrollment":20},{"nctId":"NCT06197672","phase":"PHASE1","title":"Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant","status":"RECRUITING","sponsor":"Huda Salman","startDate":"2024-03-19","conditions":"Acute Myeloid Leukemia","enrollment":30},{"nctId":"NCT05388474","phase":"","title":"A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Theratechnologies","startDate":"2022-03-22","conditions":"HIV Infections, Multi-Antiviral Resistance","enrollment":168},{"nctId":"NCT03913195","phase":"PHASE3","title":"Study of the Safety of Trogarzo™ Administered as an Undiluted \"IV Push\" or an Intramuscular Injection","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2019-05-30","conditions":"HIV-1-infection","enrollment":43},{"nctId":"NCT05502341","phase":"PHASE2, PHASE3","title":"Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2022-08-16","conditions":"HIV-1-infection","enrollment":689},{"nctId":"NCT05890963","phase":"PHASE1","title":"10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"David Ho","startDate":"2023-11-28","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT05495204","phase":"","title":"External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA","status":"COMPLETED","sponsor":"Epividian","startDate":"2022-08-05","conditions":"HIV-1-infection","enrollment":141},{"nctId":"NCT02707861","phase":"PHASE3","title":"Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced Patients With Multi-Drug Resistant HIV-1","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2016-03","conditions":"HIV","enrollment":79},{"nctId":"NCT02475629","phase":"PHASE3","title":"Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2015-08","conditions":"HIV","enrollment":40},{"nctId":"NCT01056393","phase":"PHASE2","title":"Investigator-Sponsored Protocol - Continued Use of Ibalizumab","status":"COMPLETED","sponsor":"Kaiser Permanente","startDate":"2009-11","conditions":"HIV Infections","enrollment":5},{"nctId":"NCT02028819","phase":"","title":"Compassionate Use of Ibalizumab for the Treatment of HIV Infection","status":"NO_LONGER_AVAILABLE","sponsor":"University of Colorado, Denver","startDate":"2012-01","conditions":"Human Immunodeficiency Virus (HIV)","enrollment":""},{"nctId":"NCT00784147","phase":"PHASE2","title":"Dose-Response Study of Ibalizumab (Monoclonal Antibody) Plus Optimized Background Regimen in Patients With HIV-1","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2008-08","conditions":"HIV","enrollment":113},{"nctId":"NCT01292174","phase":"PHASE1","title":"Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers","status":"COMPLETED","sponsor":"TaiMed Biologics Inc.","startDate":"2011-02","conditions":"Prevention of Infection With HIV-1","enrollment":25},{"nctId":"NCT00089700","phase":"PHASE2","title":"TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1","status":"UNKNOWN","sponsor":"Tanox","startDate":"2004-03","conditions":"HIV Infections","enrollment":80}],"_emaApprovals":[],"_faersSignals":[{"count":4,"reaction":"DRUG INEFFECTIVE"},{"count":4,"reaction":"OFF LABEL USE"},{"count":3,"reaction":"BLOOD HIV RNA INCREASED"},{"count":3,"reaction":"DYSPEPSIA"},{"count":3,"reaction":"GENOTYPE DRUG RESISTANCE TEST POSITIVE"},{"count":3,"reaction":"HEPATIC CYTOLYSIS"},{"count":3,"reaction":"HEPATITIS B"},{"count":3,"reaction":"HEPATITIS B DNA INCREASED"},{"count":3,"reaction":"PRURITUS"},{"count":2,"reaction":"ANHEDONIA"}],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Trogarzo"],"phase":"phase_3","status":"active","brandName":"ibalizumab-uiyk","genericName":"ibalizumab-uiyk","companyName":"TaiMed Biologics Inc.","companyId":"taimed-biologics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ibalizumab-uiyk is a monoclonal antibody that binds to the CD4 receptor on T cells, preventing HIV entry and replication. Used for Treatment-experienced HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}